2024 Annual Reports Reveal Diverse Trends in China’s IVD Industry

Autobio

On April 17, Autobio released its 2024 annual report. The company's operating revenue was RMB 4.471 billion, a slight increase of 0.62% year-on-year. Net profit attributable to shareholders fell 1.89% to RMB 1.194 billion. Net cash flow from operating activities decreased by 10.92% to RMB 1.309 billion.

DaAn Gene

On March 28, Guangzhou DAAN Gene Co., Ltd. reported its 2024 annual results. Operating revenue dropped 27.76% year-on-year to RMB 853 million. The company recorded a net loss attributable to shareholders of RMB 925 million, a drastic decline of 983.98%. Net cash flow from operations was RMB 300 million, down 61.5%.

Dirui

On March 28, Dirui announced its 2024 annual report. Operating revenue decreased by 11.63% to RMB 1.218 billion, while net profit attributable to shareholders plunged 48.5% to RMB 142 million. Net cash flow from operations was negative RMB 295 million, down 231.29% year-on-year.

HOB Biotech

On March 17, HOB Biotech disclosed its 2024 annual report. Operating revenue rose 2.01% to RMB 402 million, but net profit attributable to shareholders declined 22.24% to RMB 37 million. Net cash flow from operations decreased 17.16% to RMB 101 million.

Medical System

On April 18, Medical System released its 2024 annual report. Operating revenue fell 7.61% to RMB 1.742 billion, while net profit attributable to shareholders saw a marginal increase of 0.56% to RMB 258 million. Net cash flow from operations dropped 37.21% to RMB 398 million.

Novogene

On April 14, Novogene announced its 2024 annual report. Operating revenue grew 5.45% year-on-year to RMB 2.111 billion, while net profit attributable to shareholders increased 10.52% to RMB 197 million. Net cash flow from operations rose 15.36% to RMB 386 million.

Sansure Biotech

On April 18, Sansure Biotech reported its 2024 results. Operating revenue decreased by 13.29% to RMB 350 million, with a net loss attributable to shareholders of RMB 20.017 million. However, net cash flow from operations surged 228.97% to RMB 146 million.

Wantai Biotech

On April 11, Wantai Biotech released its 2024 annual report. Operating revenue plummeted 59.25% to RMB 2.245 billion, and net profit attributable to shareholders dropped sharply by 91.49% to RMB 106 million. Net cash flow from operations declined 76.91% to RMB 355 million.

Wondfo Biotech

On April 9, Wondfo Biotech released its 2024 annual report. During the reporting period, the company's operating revenue reached RMB 3.065 billion, a year-on-year increase of 10.85% compared to 2023. Net profit attributable to shareholders was RMB 562 million, up 15.18% year-on-year. Net cash flow from operating activities was RMB 362 million, a 10.05% increase from the previous year.